AU2002234591A1 - Inhibitors of the e2f-1/cyclin interaction for cancer therapy - Google Patents
Inhibitors of the e2f-1/cyclin interaction for cancer therapyInfo
- Publication number
- AU2002234591A1 AU2002234591A1 AU2002234591A AU3459102A AU2002234591A1 AU 2002234591 A1 AU2002234591 A1 AU 2002234591A1 AU 2002234591 A AU2002234591 A AU 2002234591A AU 3459102 A AU3459102 A AU 3459102A AU 2002234591 A1 AU2002234591 A1 AU 2002234591A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitors
- cancer therapy
- cyclin
- interaction
- cyclin interaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25682800P | 2000-12-20 | 2000-12-20 | |
US60/256,828 | 2000-12-20 | ||
PCT/EP2001/015006 WO2002050102A2 (en) | 2000-12-20 | 2001-12-19 | Inhibitors of the e2f-1/cyclin interaction for cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002234591A1 true AU2002234591A1 (en) | 2002-07-01 |
Family
ID=22973745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002234591A Abandoned AU2002234591A1 (en) | 2000-12-20 | 2001-12-19 | Inhibitors of the e2f-1/cyclin interaction for cancer therapy |
Country Status (8)
Country | Link |
---|---|
US (1) | US20020142966A1 (en) |
EP (1) | EP1345957A2 (en) |
JP (1) | JP2004516301A (en) |
CN (1) | CN1592752A (en) |
AU (1) | AU2002234591A1 (en) |
BR (1) | BR0116330A (en) |
CA (1) | CA2432031A1 (en) |
WO (1) | WO2002050102A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7449544B2 (en) * | 1999-11-30 | 2008-11-11 | Cyclacel Limited | p21 peptides |
WO2003063910A2 (en) * | 2002-01-28 | 2003-08-07 | Novartis Ag | β-HOMOLYSINE CONJUGATES AND THEIR USE AS TRANSPORT ENHANCER |
US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
EA017179B1 (en) * | 2011-04-06 | 2012-10-30 | Ооо "Метамакс" | Pharmaceutical composition for treating hyperproliferative diseases and use thereof |
EP3658567A1 (en) | 2017-07-28 | 2020-06-03 | Circle Pharma, Inc. | Cyclative release of peptidic compounds |
CN112608367B (en) * | 2021-03-08 | 2021-06-11 | 暨南大学 | Non-natural amino acid short peptide and application thereof in anti-tumor |
US20240218021A1 (en) * | 2022-10-21 | 2024-07-04 | Circle Pharma, Inc. | Cyclin inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7676894A (en) * | 1993-08-27 | 1995-03-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Convection-enhanced drug delivery |
US5625031A (en) * | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
GB9928323D0 (en) * | 1999-11-30 | 2000-01-26 | Cyclacel Ltd | Peptides |
-
2001
- 2001-12-19 CN CNA018210104A patent/CN1592752A/en active Pending
- 2001-12-19 JP JP2002551995A patent/JP2004516301A/en active Pending
- 2001-12-19 CA CA002432031A patent/CA2432031A1/en not_active Abandoned
- 2001-12-19 BR BR0116330-2A patent/BR0116330A/en not_active IP Right Cessation
- 2001-12-19 AU AU2002234591A patent/AU2002234591A1/en not_active Abandoned
- 2001-12-19 EP EP01985424A patent/EP1345957A2/en not_active Withdrawn
- 2001-12-19 US US10/024,935 patent/US20020142966A1/en not_active Abandoned
- 2001-12-19 WO PCT/EP2001/015006 patent/WO2002050102A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002050102A3 (en) | 2003-03-13 |
CA2432031A1 (en) | 2002-06-27 |
BR0116330A (en) | 2004-02-25 |
EP1345957A2 (en) | 2003-09-24 |
JP2004516301A (en) | 2004-06-03 |
US20020142966A1 (en) | 2002-10-03 |
CN1592752A (en) | 2005-03-09 |
WO2002050102A2 (en) | 2002-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001265296A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
AU2001282717A1 (en) | Cancer treatment by combination therapy | |
AU2001249549A1 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
AU2002239491A1 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
EP1176964B8 (en) | Uses of et743 for treating cancer | |
AUPQ923100A0 (en) | Treatment of prostate cancer | |
AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
AU2001266838A1 (en) | Inhibitors of matriptase for the treatment of cancer | |
AU2001268467A1 (en) | Identification of genes and compounds for treatment of cancer | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU2001290165A1 (en) | Components of canola for the treatment of cancer | |
AU2002217866A1 (en) | Geldanamycin derivatives useful for the treatment of cancer | |
AU6062900A (en) | Substituted indole compounds and their use for the treatment of cancer | |
AU2002239431A1 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
AU2002351374A1 (en) | Antibodies to treat cancer | |
AU1916601A (en) | Oncolytic combinations for the treatment of cancer | |
AU2002234591A1 (en) | Inhibitors of the e2f-1/cyclin interaction for cancer therapy | |
AU2001232060A1 (en) | Use of cyp1b1 inhibitors for treating cancer | |
AU7363000A (en) | Method for reducing the risk of cancer | |
AU1916501A (en) | Oncolytic combinations for the treatment of cancer | |
AU2001214116A1 (en) | Novel paclitaxel derivatives for the treatment of cancer | |
AU7636800A (en) | Improved ricin-like toxins for treatment of cancer | |
AU1595001A (en) | Oncolytic combinations for the treatment of cancer | |
AU1917101A (en) | Oncolytic combinations for the treatment of cancer | |
AU2001271284A1 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer |